NCT02676830

Evaluation of Absorption, Metabolism, and Excretion and Estimation of the Absolute Bioavailability of K-312

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Kowa Research Institute, Inc. · Industry
• Sex: Male
• Age: 25 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to Evaluation of absorption, metabolism, and excretion of \[14C\]-K-312 and estimation of the absolute bioavailability of K-312 in healthy male subjects

Conditions

• Dyslipidemia

Interventions

Type	Name	Description
DRUG	K-312 100 mg	Single oral dose
DRUG	K-312 100 ug C14 IV	microtracer dose containing ≤37 kBq (1000 nCi) \[14C\] given as a 5-ml IV push over 2 minutes

Timeline

• Start date: 2014-08-01
• Primary completion: 2015-02-01
• Completion: 2015-04-01
• First posted: 2016-02-08
• Last updated: 2016-02-18

Locations

1 site across 1 country: United States